Follow the spending 2025 R&D Expenditure against 2025 Revenue and 2024 Expenditure Reference: Top 10 pharma R&D budgets in 2025
investing
Geopolitics and Monetary Policy: Why Big Pharma Should Wait & See
Global Tensions as a Backdrop Uncertainty, not Inflation may direct the Fed's next move. As global markets react to ripples from the Iran conflict, the Fed is expected to keep current interest rates steady. Traditional economic signals are harder to interpret in the wake of geopolitical shocks; reflexive decision making can do more harm than … Continue reading Geopolitics and Monetary Policy: Why Big Pharma Should Wait & See
Biotech M&A – Three Trends to notice
Most biotech M&A coverage correctly highlights where capital is flowing, which therapeutic areas are hot, and which companies are poised to shape the future of medicine. For BD, corporate strategy, or investing, such information is useful. It gives context. It sets benchmarks. And it surfaces the big moves worth watching. But that's only part of … Continue reading Biotech M&A – Three Trends to notice
BK talks Biopharm 